The health landscape has changed significantly since 2020, following the declaration of COVID-19 as a health pandemic. Balancing the impacts of COVID-19, and the demands of implementing regulatory reforms with our core business of providing high quality regulation of therapeutic goods in Australia, continues to be both a challenge and a priority.
